Outcomes of β-blocker use in pulmonary arterial hypertension: A propensity-matched analysis

European Respiratory Journal

Volumn 46, Issue 3, 2015, Pages 750-760

  Bandyopadhyay, Debabrata ^a   Bajaj, Navkaranbir S ^b   Zein, Joe ^a   Minai, Omar A ^a   Dweik, Raed A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; METOPROLOL;

ADULT; ARTICLE; CAUSE OF DEATH; COMORBIDITY; CONTROLLED STUDY; DRUG SAFETY; DYSPNEA; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; HYPOTENSION; LUNG HEMODYNAMICS; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEW YORK HEART ASSOCIATION CLASS; OVERALL SURVIVAL; PREVALENCE; PRIORITY JOURNAL; PROBABILITY; PROPENSITY SCORE; PULMONARY ARTERY OCCLUSION PRESSURE; PULMONARY HYPERTENSION; SURVIVAL TIME; TREATMENT DURATION; TREATMENT OUTCOME; AGED; CASE CONTROL STUDY; COMPARATIVE STUDY; CONFIDENCE INTERVAL; DRUG EFFECTS; EVALUATION STUDY; HYPERTENSION, PULMONARY; KAPLAN MEIER METHOD; LUNG WEDGE PRESSURE; MIDDLE AGED; NONPARAMETRIC TEST; PROGNOSIS; REFERENCE VALUE; REGISTER; RETROSPECTIVE STUDY; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; CASE-CONTROL STUDIES; CAUSE OF DEATH; CONFIDENCE INTERVALS; FEMALE; HUMANS; HYPERTENSION, PULMONARY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROGNOSIS; PULMONARY WEDGE PRESSURE; REFERENCE VALUES; REGISTRIES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84942752406     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00215514     Document Type: Article

References (23)

1. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991; 115: 343-349.
2. Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010; 122: 156-163.
3. Reybrouck T, Amery A, Billiet L. Hemodynamic response to graded exercise after chronic beta-adrenergic blockade. J Appl Physiol Respir Environ Exerc Physiol 1977; 42: 133-138.
4. Peacock A, Ross K. Pulmonary hypertension: a contraindication to the use of β-adrenoceptor blocking agents. Thorax 2010; 65: 454-455.
5. Velez-Roa S, Ciarka A, Najem B, et al. Increased sympathetic nerve activity in pulmonary artery hypertension. Circulation 2004; 110: 1308-1312.
6. Minai OA, Gudavalli R, Mummadi S, et al. Heart rate recovery predicts clinical worsening in patients with pulmonary arterial hypertension. Am J Respir Crit Care Med 2012; 185: 400-408.
7. Wensel R, Jilek C, Dörr M, et al. Impaired cardiac autonomic control relates to disease severity in pulmonary hypertension. Eur Respir J 2009; 34: 895-901.
8. Naeije R, van de Borne P. Clinical relevance of autonomic nervous system disturbances in pulmonary arterial hypertension. Eur Respir J 2009; 34: 792-794.
9. Bogaard HJ, Natarajan R, Mizuno S, et al. Adrenergic receptor blockade reverses right heart remodeling and dysfunction in pulmonary hypertensive rats. Am J Respir Crit Care Med 2010; 182: 652-660.
10. Drake JI, Gomez-Arroyo J, Dumur CI, et al. Chronic carvedilol treatment partially reverses the right ventricular failure transcriptional profile in experimental pulmonary hypertension. Physiol Genomics 2013; 45: 449-461.
11. de Man FS, Handoko ML, van Ballegoij JJ, et al. Bisoprolol delays progression towards right heart failure in experimental pulmonary hypertension. Circ Heart Fail 2012; 5: 97-105.
12. Tonelli AR, Plana JC, Heresi GA, et al. Prevalence and prognostic value of left ventricular diastolic dysfunction in idiopathic and heritable pulmonary arterial hypertension. Chest 2012; 141: 1457-1465.
13. Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2013; 62: Suppl. 25, D34-D41.
14. Provencher S, Herve P, Jais X, et al. Deleterious effects of β-blockers on exercise capacity and hemodynamics in patients with portopulmonary hypertension. Gastroenterology 2006; 130: 120-126.
15. So PP, Davies RA, Chandy G, et al. Usefulness of beta-blocker therapy and outcomes in patients with pulmonary arterial hypertension. Am J Cardiol 2012; 109: 1504-1509.
16. Thenappan T, Roy SS, Duval S, et al. β-blocker therapy is not associated with adverse outcomes in patients with pulmonary arterial hypertension: a propensity score analysis. Circ Heart Fail 2014; 7: 903-910.
17. de Man FS, Handoko ML, Guignabert C, et al. Neurohormonal axis in patients with pulmonary arterial hypertension: friend or foe? Am J Respir Crit Care Med 2013; 187: 14-19.
18. Chazova IE, Irodova NL, Krasnikova TL, et al. [Primary pulmonary hypertension: activation of sympathico-adrenal system and free radical oxidation. Positive effects of carvedilol therapy]. Ter Arkh 2005; 77: 66-72.
19. Dimopoulos S, Anastasiou-Nana M, Katsaros F, et al. Impairment of autonomic nervous system activity in patients with pulmonary arterial hypertension: a case control study. J Card Fail 2009; 15: 882-889.
20. Hoeper MM, Pletz MW, Golpon H, et al. Prognostic value of blood gas analyses in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2007; 29: 944-950.
21. Holverda S, Gan CT, Marcus JT, et al. Impaired stroke volume response to exercise in pulmonary arterial hypertension. J Am Coll Cardiol 2006; 47: 1732-1733.
22. Bouallal R, Godart F, Francart C, et al. Interest of β-blockers in patients with right ventricular systemic dysfunction. Cardiol Young 2010; 20: 615-619.
23. Martyniuk TV, Konosova ID, Chazova IE. [Use of nebivolol in patients with idiopathic pulmonary hypertension: results of the pilot study]. Ter Arkh 2012; 84: 49-53.